treatment of radiogenic ulcers. Biotecnol Apl 1993; 10:12.
14- Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled doubleblind study. Diabetes Care 1998; 21:822–7.
15- Berlanga J, Lodos J, Labarta V, Merino N, Gonzalez T, Hayes O, Puentes P, Mulet J, Lopez-Saura P. The effect of the epidermal growth factor treatment schedule on the healing of full-thickness wounds in pigs. Biotecnol Apl 1997; 14:163–8.
16- Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY, Kam G, Leung L, Chan CW, Chu CM, Lam EK. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003; 26:1856–61.
17- Brown GL, Nanney LB, Griffen J, Cramer AB, Yancey JM, Curtsinger LJ, Holtzin L, Schultz GS, Jurkiewicz MJ, Lynch JB. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989; 321:76–9.
18- Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999; 7:335–46.